170 related articles for article (PubMed ID: 30166585)
21. Antiprion properties of prion protein-derived cell-penetrating peptides.
Löfgren K; Wahlström A; Lundberg P; Langel U; Gräslund A; Bedecs K
FASEB J; 2008 Jul; 22(7):2177-84. PubMed ID: 18296502
[TBL] [Abstract][Full Text] [Related]
22. Structural insight into the antiprion compound inhibition mechanism of native prion folding over misfolding.
Choi J; Govindaraj RG; Hyeon JW; Lee K; Ma S; Kim SY; Lee J; No KT
Chem Biol Drug Des; 2017 Jun; 89(6):907-917. PubMed ID: 27933736
[TBL] [Abstract][Full Text] [Related]
23. Cyclodextrins inhibit replication of scrapie prion protein in cell culture.
Prior M; Lehmann S; Sy MS; Molloy B; McMahon HE
J Virol; 2007 Oct; 81(20):11195-207. PubMed ID: 17699584
[TBL] [Abstract][Full Text] [Related]
24. Styryl-based and tricyclic compounds as potential anti-prion agents.
Chung E; Prelli F; Dealler S; Lee WS; Chang YT; Wisniewski T
PLoS One; 2011; 6(9):e24844. PubMed ID: 21931860
[TBL] [Abstract][Full Text] [Related]
25. Ethanolamine Is a New Anti-Prion Compound.
Uchiyama K; Hara H; Chida J; Pasiana AD; Imamura M; Mori T; Takatsuki H; Atarashi R; Sakaguchi S
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769172
[TBL] [Abstract][Full Text] [Related]
26. New approaches for the selection and evaluation of anti-prion organic compounds.
Cordeiro Y; Ferreira NC
Mini Rev Med Chem; 2015; 15(2):84-92. PubMed ID: 25723455
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibodies inhibit prion replication and delay the development of prion disease.
White AR; Enever P; Tayebi M; Mushens R; Linehan J; Brandner S; Anstee D; Collinge J; Hawke S
Nature; 2003 Mar; 422(6927):80-3. PubMed ID: 12621436
[TBL] [Abstract][Full Text] [Related]
28. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells.
Ertmer A; Gilch S; Yun SW; Flechsig E; Klebl B; Stein-Gerlach M; Klein MA; Schätzl HM
J Biol Chem; 2004 Oct; 279(40):41918-27. PubMed ID: 15247213
[TBL] [Abstract][Full Text] [Related]
29. [Mechanisms of prion transmission].
Sakaguchi S
Nihon Rinsho; 2007 Aug; 65(8):1391-5. PubMed ID: 17695274
[TBL] [Abstract][Full Text] [Related]
30. Antiprion Activity of DB772 and Related Monothiophene- and Furan-Based Analogs in a Persistently Infected Ovine Microglia Culture System.
Dinkel KD; Stanton JB; Boykin DW; Stephens CE; Madsen-Bouterse SA; Schneider DA
Antimicrob Agents Chemother; 2016 Sep; 60(9):5467-82. PubMed ID: 27381401
[TBL] [Abstract][Full Text] [Related]
31. Disulfide-crosslink scanning reveals prion-induced conformational changes and prion strain-specific structures of the pathological prion protein PrP
Taguchi Y; Lu L; Marrero-Winkens C; Otaki H; Nishida N; Schatzl HM
J Biol Chem; 2018 Aug; 293(33):12730-12740. PubMed ID: 29934306
[TBL] [Abstract][Full Text] [Related]
32. Discovery of a class of diketopiperazines as antiprion compounds.
Bolognesi ML; Ai Tran HN; Staderini M; Monaco A; López-Cobeñas A; Bongarzone S; Biarnés X; López-Alvarado P; Cabezas N; Caramelli M; Carloni P; Menéndez JC; Legname G
ChemMedChem; 2010 Aug; 5(8):1324-34. PubMed ID: 20540064
[TBL] [Abstract][Full Text] [Related]
33. Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation.
Cardinale A; Filesi I; Vetrugno V; Pocchiari M; Sy MS; Biocca S
J Biol Chem; 2005 Jan; 280(1):685-94. PubMed ID: 15513919
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells.
Yamasaki T; Suzuki A; Hasebe R; Horiuchi M
PLoS One; 2014; 9(9):e106516. PubMed ID: 25181483
[TBL] [Abstract][Full Text] [Related]
35. Theoretical study of the prion protein based on the fragment molecular orbital method.
Ishikawa T; Ishikura T; Kuwata K
J Comput Chem; 2009 Dec; 30(16):2594-601. PubMed ID: 19408278
[TBL] [Abstract][Full Text] [Related]
36. Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time.
Mayer-Sonnenfeld T; Avrahami D; Friedman-Levi Y; Gabizon R
Cell Mol Neurobiol; 2008 Nov; 28(7):1005-15. PubMed ID: 18350378
[TBL] [Abstract][Full Text] [Related]
37. Mechanistic insights into the cure of prion disease by novel antiprion compounds.
Webb S; Lekishvili T; Loeschner C; Sellarajah S; Prelli F; Wisniewski T; Gilbert IH; Brown DR
J Virol; 2007 Oct; 81(19):10729-41. PubMed ID: 17652397
[TBL] [Abstract][Full Text] [Related]
38. Prion inhibition with multivalent PrPSc binding compounds.
Mays CE; Joy S; Li L; Yu L; Genovesi S; West FG; Westaway D
Biomaterials; 2012 Oct; 33(28):6808-22. PubMed ID: 22748770
[TBL] [Abstract][Full Text] [Related]
39. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
[TBL] [Abstract][Full Text] [Related]
40. Effects of new amphotericin analogues on the scrapie isoform of the prion protein.
Soler L; Caffrey P; McMahon HE
Biochim Biophys Acta; 2008 Oct; 1780(10):1162-7. PubMed ID: 18691635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
